Prima BioMed Ltd (PBMD), said Wednesday that it has signed a non-binding memorandum of understanding with WuXi Biologics, an open-access R&D capability and technology platform company, to form a strategic biologics development and manufacturing partnership.
Under the partnership, WuXi Biologics will be the exclusive clinical manufacturer for IMP321 for Prima worldwide, excluding any manufacturing for the supply of China, Macau, Taiwan and Hong Kong where rights are retained by Prima’s development partner in China, Eddingpharm. WuXi Biologics will also be Prima’s preferred partner to manufacture potential new products.
IMP321, a first-in-class soluble LAG-3 Ig fusion protein and an APC activator boosting T cell responses for cancer chemo-immunotherapy is currently in Phase II trials in Europe. PBMD shares were up 2.6% in recent trade.